Less than a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it publishes its initial advice on the medications.
Given more than one billion individuals worldwide currently obese, it is urging increased and just availability to GLP-1 medication.
According to estimates, more than two billion will be obese by 2030 unless action is taken.
"The latest guidance recognises that obesity is a chronic disease that can be addressed with holistic and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing substantial body mass, explains the agency.
Skinny Jab Shortage
Despite the present best projected case, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation urges countries and companies to widen availability, by approaches including voluntary licensing.
A patent on semaglutide – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a biological compound to slow digestion, curb appetite and increase satiety so individuals eat less.
People commonly see weight reduction within a few weeks of starting on the weekly injections.
Studies suggests people may regain a significant portion after a year of halting the medication, because their typical appetite resume.
To be carrying excess weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the WHO.
